Tag: Neutropenia
FDA Grants RMAT Designation To Cellerant’s “Off-The-Shelf” Romyelocel-L Cell Therapy
Cellerant Therapeutics Inc., is a clinical-stage company developing innovative cell and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s romyelocel-L (human myeloid progenitor cells) “off-the-shelf” cell therapy does not require HLA matching and is designed to prevent...
